|
Search for our Investigators on Pub
Med
|
MICHAEL D. WYATT , Ph.D. Lab
LAB PERSONNEL
Mike Wyatt - Assistant Professor, USC
PUBLICATIONS
Sen S, Paraggio NA, Gearheart LA, Connor EE, Issa A, Coleman
RS, Wilson Iii DM, Wyatt MD, Berg MA. Effect of Protein
Binding on Ultrafast DNA Dynamics: Characterization of a
DNA:APE1 Complex. Biophys J. 2005 Sep 30
Li L, Connor EE, Berger SH, Wyatt MD.
Determination of apoptosis, uracil incorporation, DNA strand
breaks, and sister chromatid exchanges under conditions of
thymidylate deprivation in a model of BER deficiency.
Biochem Pharmacol. 2005 Sep 24
Connor EE, Wilson JJ, Wyatt MD. Effects of substrate
specificity on initiating the base excision repair of N-methylpurines
by variant human 3-methyladenine DNA glycosylases. Chem Res
Toxicol. 2005 Jan;18(1):87-94.
Hitchcock TM, Dong L, Connor EE, Meira LB, Samson LD, Wyatt
MD, Cao W. Oxanine DNA glycosylase activity from Mammalian
alkyladenine glycosylase. J Biol Chem. 2004 Sep
10;279(37):38177-83.
Li L, Berger SH, Wyatt MD. Involvement of base excision
repair in response to therapy targeted at thymidylate
synthase. Mol Cancer Ther. 2004 Jun;3(6):747-53.
Connor EE, Wyatt MD. Active-site clashes prevent the human
3-methyladenine DNA glycosylase from improperly removing
bases. Chem Biol. 2002 Sep;9(9):1033-41.
Lau AY, Wyatt MD, Glassner BJ, Samson LD, Ellenberger T.
Molecular basis for discriminating between normal and
damaged bases by the human alkyladenine glycosylase, AAG.
Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13573-8.
Wyatt MD, Samson LD. Influence of DNA structure on
hypoxanthine and 1,N(6)-ethenoadenine removal by murine
3-methyladenine DNA glycosylase. Carcinogenesis. 2000
May;21(5):901-8.
Wyatt MD, Allan JM, Lau AY, Ellenberger TE, Samson LD.
3-methyladenine DNA glycosylases: structure, function, and
biological importance. Bioessays. 1999 Aug;21(8):668-76.
Allan JM, Engelward BP, Dreslin AJ, Wyatt MD, Tomasz M,
Samson LD. Mammalian 3-methyladenine DNA glycosylase
protects against the toxicity and clastogenicity of certain
chemotherapeutic DNA cross-linking agents. Cancer Res. 1998
Sep 1;58(17):3965-73.
Hartley JA, Wyatt MD. Determination of the DNA sequence
specificity of alkylation damage using cleavage-based
assays. Methods Mol Biol. 1997;90:147-56.
Bailey SM, Wyatt MD, Friedlos F, Hartley JA, Knox RJ, Lewis
AD, Workman P. Involvement of DT-diaphorase (EC 1.6.99.2) in
the DNA cross-linking and sequence selectivity of the
bioreductive anti-tumour agent EO9. Br J Cancer.
1997;76(12):1596-603.
Engelward BP, Weeda G, Wyatt MD, Broekhof JL, de Wit J,
Donker I, Allan JM, Gold B, Hoeijmakers JH, Samson LD. Base
excision repair deficient mice lacking the Aag alkyladenine
DNA glycosylase. Proc Natl Acad Sci U S A. 1997 Nov
25;94(24):13087-92.
Wyatt MD, Lee M, Hartley JA. The sequence specificity of
alkylation for a series of benzoic acid mustard and
imidazole-containing distamycin analogues: the importance of
local sequence conformation. Nucleic Acids Res. 1997 Jun
15;25(12):2359-64.
Wyatt MD, Lee M, Hartley JA. Alkylation specificity for a
series of distamycin analogues that tether chlorambucil.
Anticancer Drug Des. 1997 Jan;12(1):49-60.
Wyatt MD, Lee M, Garbiras BJ, Souhami RL, Hartley JA.
Sequence specificity of alkylation for a series of nitrogen
mustard-containing analogues of distamycin of increasing
binding site size: evidence for increased cytotoxicity with
enhanced sequence specificity. Biochemistry. 1995 Oct
10;34(40):13034-41.
Hartley JA, Webber J, Wyatt MD, Bordenick N, Lee M. Novel
cytotoxic DNA sequence and minor groove targeted
photosensitizers: conjugates of pyrene and netropsin
analogues. Bioorg Med Chem. 1995 Jun;3(6):623-9.
Hartley JA, Preti CS, Wyatt MD, Lee M. Design, synthesis and
biological evaluation of benzoic acid mustard derivatives of
imidazole-containing and C-terminal carboxamide analogues of
distamycin. Drug Des Discov. 1995 Apr;12(4):323-35.
Broggini M, Coley HM, Mongelli N, Pesenti E, Wyatt MD,
Hartley JA, D'Incalci M. DNA sequence-specific adenine
alkylation by the novel antitumor drug tallimustine (FCE
24517), a benzoyl nitrogen mustard derivative of distamycin.
Nucleic Acids Res. 1995 Jan 11;23(1):81-7.
Wyatt MD, Garbiras BJ, Haskell MK, Lee M, Souhami RL,
Hartley JA. Structure-activity relationship of a series of
nitrogen mustard- and pyrrole-containing minor
groove-binding agents related to distamycin. Anticancer Drug
Des. 1994 Dec;9(6):511-25.
Lee M, Preti CS, Vinson E, Wyatt MD, Hartley JA. GC sequence
specific recognition by an N-formamido, C-terminus-modified
and imidazole-containing analogue of netropsin. J Med Chem.
1994 Nov 25;37(24):4073-5.
Lee M, Rhodes AL, Wyatt MD, Forrow S, Hartley JA. Design,
synthesis, and biological evaluation of DNA sequence and
minor groove selective alkylating agents. Anticancer Drug
Des. 1993 Jun;8(3):173-92.
Lee M, Rhodes AL, Wyatt MD, Forrow S, Hartley JA. GC base
sequence recognition by oligo(imidazolecarboxamide) and
C-terminus-modified analogues of distamycin deduced from
circular dichroism, proton nuclear magnetic resonance, and
methidiumpropylethylenediaminetetraacetate-iron(II)
footprinting studies. Biochemistry. 1993 Apr
27;32(16):4237-45.
Lee M, Rhodes AL, Wyatt MD, D'Incalci M, Forrow S, Hartley
JA. In vitro cytotoxicity of GC sequence directed alkylating
agents related to distamycin. J Med Chem. 1993 Apr
2;36(7):863-70.
For recent abstracts,
click here
|
